Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
856 questions in 87 reviews · Cystic Fibrosis and Genetic Disorders
current versionsNo studies 856 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Deferasirox vs placebo Satisfaction with treatment · people with non‐transfusion‐dependent thalassemia Deferasirox for managing iron overload in people with thalassaemia (2017) · Cochrane | no estimate extracted | NR | No studies |
Deferasirox vs deferiprone Responder analysis · people with transfusion‐dependent thalassemia Deferasirox for managing iron overload in people with thalassaemia (2017) · Cochrane | no estimate extracted | NR | No studies |
High‐dose vs low‐dose rFVIIa AJBR · adults and children with hemophilia A or B with inhibitors Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors (2017) · Cochrane | no estimate extracted | NR | No studies |
High‐dose vs low‐dose rFVIIa Quality of life · adults and children with hemophilia A or B with inhibitors Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors (2017) · Cochrane | no estimate extracted | NR | No studies |
Beta‐2 agonists vs placebo Participant‐reported outcomes: quality of life (measured by CFQ‐R) · adults and children with cystic fibrosis Long‐acting inhaled bronchodilators for cystic fibrosis (2017) · Cochrane | no estimate extracted | NR | No studies |
Beta‐2 agonists vs placebo Adverse events after tiotropium 5.0 µg · adults and children with cystic fibrosis Long‐acting inhaled bronchodilators for cystic fibrosis (2017) · Cochrane | no estimate extracted | NR | No studies |
Beta‐2 agonists vs placebo Pulmonary exacerbations · adults and children with cystic fibrosis Long‐acting inhaled bronchodilators for cystic fibrosis (2017) · Cochrane | no estimate extracted | NR | No studies |
Beta‐2 agonists vs placebo Other measures of lung function · adults and children with cystic fibrosis Long‐acting inhaled bronchodilators for cystic fibrosis (2017) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Changes in globotriaosylceramide (Gb3) concentration in plasma and tissue · Anderson‐Fabry disease Enzyme replacement therapy for Anderson‐Fabry disease (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Pain Acroparaesthesia and Fabry crises · Anderson‐Fabry disease Enzyme replacement therapy for Anderson‐Fabry disease (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Renal function · Anderson‐Fabry disease Enzyme replacement therapy for Anderson‐Fabry disease (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Symptoms and complications of disease: cerebrovascular events · Anderson‐Fabry disease Enzyme replacement therapy for Anderson‐Fabry disease (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Death · Anderson‐Fabry disease Enzyme replacement therapy for Anderson‐Fabry disease (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Symptoms and complications of disease:cardiac events · Anderson‐Fabry disease Enzyme replacement therapy for Anderson‐Fabry disease (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Symptoms and complications of disease: cerebrovascular events · Anderson‐Fabry disease Enzyme replacement therapy for Anderson‐Fabry disease (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Pain · Anderson‐Fabry disease Enzyme replacement therapy for Anderson‐Fabry disease (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Patient‐reported signs and symptoms/ self‐management · patients with sickle cell disease Interventions for patients and caregivers to improve knowledge of sickle cell disease and recognition of its… (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Caregiver‐reported signs and symptoms Lead to self management · caregivers of patients with sickle cell disease Interventions for patients and caregivers to improve knowledge of sickle cell disease and recognition of its… (2016) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ Exercise vs no intervention Adverse events · participants with haemophilia Exercise for haemophilia (2016) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ Exercise alone vs exercise plus electrophysical modality Adverse events · participants with haemophilia Exercise for haemophilia (2016) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ Exercise alone vs exercise plus electrophysical modality Quality of life · participants with haemophilia Exercise for haemophilia (2016) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ Exercise alone vs exercise plus electrophysical modality Pain · participants with haemophilia Exercise for haemophilia (2016) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ Exercise alone vs exercise plus electrophysical modality Functional Status · participants with haemophilia Exercise for haemophilia (2016) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ Exercise vs no intervention Quality of life · participants with haemophilia Exercise for haemophilia (2016) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ Hydrotherapy vs no exercise Adverse events · participants with haemophilia Exercise for haemophilia (2016) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ Hydrotherapy vs no exercise Quality of life · participants with haemophilia Exercise for haemophilia (2016) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ Hydrotherapy vs no exercise Pain · participants with haemophilia Exercise for haemophilia (2016) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ Hydrotherapy vs no exercise Functional status · participants with haemophilia Exercise for haemophilia (2016) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ Exercise vs no intervention Functional Status · participants with haemophilia Exercise for haemophilia (2016) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ Exercise A vs Exercise B Adverse events · participants with haemophilia Exercise for haemophilia (2016) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ Exercise A vs Exercise B Quality of life · participants with haemophilia Exercise for haemophilia (2016) · Cochrane | no estimate extracted | NR | No studies |
Hydroxyurea vs placebo or standard care Frequency of transfusion · people with non‐transfusion dependent beta thalassaemia Hydroxyurea for reducing blood transfusion in non‐transfusion dependent beta thalassaemias (2016) · Cochrane | no estimate extracted | NR | No studies |
Hydroxyurea vs placebo or standard care Major adverse effects · people with non‐transfusion dependent beta thalassaemia Hydroxyurea for reducing blood transfusion in non‐transfusion dependent beta thalassaemias (2016) · Cochrane | no estimate extracted | NR | No studies |
Hydroxyurea vs placebo or standard care Quality of life · people with non‐transfusion dependent beta thalassaemia Hydroxyurea for reducing blood transfusion in non‐transfusion dependent beta thalassaemias (2016) · Cochrane | no estimate extracted | NR | No studies |
Hydroxyurea vs placebo or standard care Mean Hb F (g/dL) · people with non‐transfusion dependent beta thalassaemia Hydroxyurea for reducing blood transfusion in non‐transfusion dependent beta thalassaemias (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Frequency of transfusion · people with non‐transfusion dependent beta thalassaemia Hydroxyurea for reducing blood transfusion in non‐transfusion dependent beta thalassaemias (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Quality of life · people with non‐transfusion dependent beta thalassaemia Hydroxyurea for reducing blood transfusion in non‐transfusion dependent beta thalassaemias (2016) · Cochrane | no estimate extracted | NR | No studies |
Oral antibiotics vs IV antibiotics Time to next exacerbation · people with cystic fibrosis experiencing a pulmonary exacerbation Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis (2015) · Cochrane | no estimate extracted | NR | No studies |
Oral antibiotics vs IV antibiotics Quality of life · people with cystic fibrosis experiencing a pulmonary exacerbation Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis (2015) · Cochrane | no estimate extracted | NR | No studies |
Single vs combination IV antibiotics Quality of life · people with cystic fibrosis experiencing a pulmonary exacerbation Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis (2015) · Cochrane | no estimate extracted | NR | No studies |
Nebulised antibiotics vs IV antibiotics Time to next exacerbation · people with cystic fibrosis experiencing a pulmonary exacerbation Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis (2015) · Cochrane | no estimate extracted | NR | No studies |
Nebulised antibiotics vs IV antibiotics Quality of life · people with cystic fibrosis experiencing a pulmonary exacerbation Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis (2015) · Cochrane | no estimate extracted | NR | No studies |
Dalteparin vs placebo Pain duration ‐ not measured · patients with people with sickle cell disease Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease (2015) · Cochrane | no estimate extracted | NR | No studies |
Dalteparin vs placebo The requirement for opiate treatment ‐ not measured · patients with people with sickle cell disease Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease (2015) · Cochrane | no estimate extracted | NR | No studies |
Dalteparin vs placebo Number of serious complications of SCD ‐ not measured · patients with people with sickle cell disease Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease (2015) · Cochrane | no estimate extracted | NR | No studies |
Dalteparin vs placebo Number of other sickle‐related events ‐ not measured · patients with people with sickle cell disease Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease (2015) · Cochrane | no estimate extracted | NR | No studies |
Dalteparin vs placebo Quality of life (e.g. absence from school, lost time at work, mobility) as assessed by any validated questionnaire either generic or SCD specific) ‐ not measured · patients with people with sickle cell disease Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease (2015) · Cochrane | no estimate extracted | NR | No studies |
Dalteparin vs placebo Hospitalisation (number and duration) ‐ not measured · patients with people with sickle cell disease Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease (2015) · Cochrane | no estimate extracted | NR | No studies |
Dalteparin vs placebo Participant satisfaction with the medication assessed by any appropriate and validated questionnaire (either generic or SCD specific) ‐ not measured · patients with people with sickle cell disease Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease (2015) · Cochrane | no estimate extracted | NR | No studies |
Dalteparin vs placebo Adverse events associated with the use of anticoagulants (e.g. bleeding) ‐ not measured · patients with people with sickle cell disease Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease (2015) · Cochrane | no estimate extracted | NR | No studies |